Skip to content
DataLookout
Menu

NCT03290950

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 18 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 43 words
    • Study completion pushed from Sep 2026 to Sep 2027
    • Publications: details revised at 1 of 1 entry
  2. Notable Results first posted: May 29, 2026
    • Primary endpoint revised
    • Enrollment target: 75 to 69
    v24
  3. Minor Primary completion date changed from estimate of Sep 2026 to May 21, 2025v22
  4. Notable Primary and study completion dates: Sep 2025 to Sep 2026v21
  5. Notable Primary and study completion dates: Sep 2024 to Sep 2025v19
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Primary and study completion dates: Sep 2023 to Sep 2024
    • Study sites revised (7)
    v18
  2. Notable Primary and study completion dates: Sep 2022 to Sep 2023v15
  3. Notable Primary and study completion dates: Sep 2021 to Sep 2022v14
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 41 to confirmed 75
    • Site details revised at 7 of 7 sites
    v12
  5. Minor Site contacts updated at 6 of 7 sitesv11
  6. Notable Primary and study completion dates: Sep 2020 to Sep 2021
    • Eligibility criteria revised
    • Study sites: 8 to 7
    v10
  7. Notable Eligibility criteria expanded, about 130 words
    • Study sites: 7 to 8
    v9
  8. Notable Primary and study completion dates: Sep 2019 to Sep 2020v8
  9. Minor Study sites: 6 to 7
    • Interventions: carfilzomib (Drug), daratumumab (Drug), dexamethasone (Drug), lenalidomide (Drug) to carfilzomib (Drug), daratumumab (Drug), dexamethasone (Drug), dexamethasone (Drug), lenalidomide (Drug)
    • Study arms: 1 to 2
    v6
  10. Notable Eligibility criteria revisedv4
  11. Notable Primary completion date: Sep 2017 to Sep 2019
    • Start date changed from estimate of Sep 2017 to Sep 25, 2017
    v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 6 of 6 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Best Overall Response
Timeframe: Up to 8 cycles

Arms and interventions

Cohort 1Experimental

Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.

Cohort 2Experimental

Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.

Drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone

Sites

7 sites in 1 country